AIDS and drug rationing
,
Abstract
Financial shortage in resource-limited and poor countries restricts treatment in HIV-infected patients especially in poor countries. Higher HIV prevalence in poorer countries makes drug rationing a real concern. Different countries solve the problem with different methods regarding WHO guidelines, but fairness and equity should be a major consideration in drug rationing. This paper is aimed at reviewing different strategic approaches to drug rationing in AIDS treatment and then discusses pharmacists' role. In conclusion, there is no fair and equitable strategy, and in each society, cultural, ethical and socioeconomic issues along with considering a critical role for pharmacists must be taken into account.
Bayer R, Stryker J. Ethical challenges posed by clinical progress in AIDS. Am J Public Health 1997; 87: 1599-1602.
Anonymous. UNAIDS. Report on the global AIDS ephdemic. Geneva: UNAIDS; 2008. a. http://www.unaids.org/en/KnowledgeCentre/HIVData/GlobalReport/2008/2008_Global_report.asp (accessed on Sep 2009)
Anonymous. World Health Organization. Treating 3 million by 2005: making it happen. The WHO Strategy. Geneva: World Health Organization; 2003. http://www.who.int/3by5/publications/documents/en/3by5StrategyMakingItHappen.pdf (accessed on Oct 2009)
Anonymous. World Health Organization. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector, progress report; 2009. http://www.who.int/hiv/pub/2009progressreport/en/index.html (accessed on Oct 2009)
Anonymous. National AIDS Committee Secretariat, Ministry of Health and Medical Education of the Islamic Republic of Iran. Islamic Republic of Iran Country Report on Monitoring of the United Nations General Assembly Special Session on HIV and AIDS; January 2008. http://data.unaids.org/pub/Report/2008/iran_2008_country_progress_report_en.pdf (accessed on Sep 2009)
Walensky RP, Paltieil AD, Losina E, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis 2006; 194: 11-19.
Lohse N, Hansen AB, Pedersen G, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 2007; 146: 87-95.
Bisson GP, Frank I, Gross R, et al. Out-of-pocket costs of HAART limits HIV treatment responses in Botswana's private sector. AIDS 2006; 20: 1333-6.
Braitstein P, Prinkhof MW, Dabis F, et al. Mortality of HIV-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367: 817-24.
Yeni P, Cooper DA, Aboulker JP, et al. Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomized trial. Lancet 2006; 368: 287-98.
Anonymous. World Health Organization. Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach to 2003 revision. Geneva: World Health Organization, 2003. http://www.who.int/hiv/pub/prev_care/en/arvrevision2003en.pdf (accessed on Oct 2009)
Auvert B, Males S, Puren A, Taljaard D, Carael M, Williams B. Can highly active antiretroviral therapy reduce the spread of HIV? J Acquir Immune Defic Syndr 2004; 36: 613-21.
Abbas UL, Anderson RM, Mellors JW. Potential impact of antiretroviral therapy on HIV-1 transmission and AIDS mortality in resource-limited settings. J Acquir Immune Defic Syndr 2006; 41: 632-41.
Rowley JT, Anderson RM, Ng TW. Reducing the spread of HIV infection in sub-Saharan Africa: some demographic and economic implications. AIDS 1990; 4: 47-56.
Anonymous. World Health Organization. Prioritizing second-line antiretroviral drugs for adults and adolescents: a public health approach. Geneva; 2007. http://www.who.int/hiv/pub/meetingreports/art_meeting/en/index.html (accessed on Oct 2009)
Anonymous. World Health Organization. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector; Progress report, 2009. http://www.who.int/hiv/pub/2009progressreport/en/print.html (accessed on Oct 2009)
Doyle A, Jefferys R. National ADAP monitoring project: annual report, March 2000. Washington, DC: National alliance of State and Territorial AIDS Directors and AIDS Treatment Data Network, 2000.
Anonymous. National Alliance of State and Territorial AIDS Directors. State AIDS drug assistance programs: A national status report on access. Washington DC: national Alliance of State and Territorial AIDS Directors and The AIDS Treatment Data Network, 1997. http://www.atdn.org/access/adap/report.html (accessed on Oct 2009)
Mitka M. MTCT-Plus program has two goals: end maternal HIV transmission + treat mothers. JAMA 2002; 288: 153-4.
Rosen S, Sanne I, Collier A, Simon J. Hard choices: rationing antiretroviral therapy for Africa. Lancet 2005; 365: 354-6.
Wilson DP, Blower SM. Rational choices for allocating antiretrovirals in Africa: treatment equity, epidemiological efficiency, and feasibility. PLoS Medicine 2006; 3(3): e160.
Zhou J, Kumarasamay N. Predicting short-term disease progression among HIV-infected patients in Asia and the Pacific region: preliminary results from the TREAT Asia HIV Observational database (TAHOD). HIV Med 2005; 6: 216-23.
Calmy A, Pinoges L, Szumilin E, Zachariah R, Ford N, Ferradini L. Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort. AIDS 2006; 20: 1163-9.
De Simone JA, Pomerantz RJ, Babinchak TJ. Inflammatory reactions in HIV-1 infected persons after initiation of highly active antiretroviral therapy. Ann Intern Med 2000; 133: 447-54.
Rosen S, Sanne I, Collier A, Simon JL. Rationing antiretroviral therapy for HIV/AIDS in Africa: choices and consequences. PLoS Medicine 2005; 2(11): 1098-1104.
Zaric GS, Brandeau ML. Optimal investment in a portfolio of HIV prevention programs. Med Decis Making 2001; 21(5): 391-408.
Zaric GS, Brandeau ML. A little planning goes a long way: multilevel allocation of HIV prevention resources. Med Decis Making 2007; 27: 71-81.
Anonymous. World Health Organization. Draft Guidelines for Surveillance of HIV Drug Resistance. Geneva: World Health Organization; 2003. http://www.who.int/3by5/publications/guidelines/en/execsumm.pdf (accessed on Oct 2009)
Spacek LA, Shihab HM, Kamaya MR, et al. Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala. Clin Infect Dis 2006; 42: 252-9.
Orrell C, Bangsberg DR, Badri M, Wood R. Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS 2003; 17: 1369-75.
Stevens W, Kaye S, Corrah T. Antiretroviral therapy in Africa. BMJ 2004; 328: 280-2.
Walensky RP, Weinstein MC, Yazdanpanah Y, et al. HIV drug resistance surveillance for prioritizing treatment in resource-limited settings. AIDS 2007; 21: 973-82.
Baker JV, Peng G, Rapkin J, et al. Poor initial CD4+ recovery with antiretroviral therapy prolongs immune depletion and increases risk for AIDS and non-AIDS diseases. J Acquir Immune Defic Syndr 2008; 48: 541-6.
Ledergerber B, Lundgren JD, Walker AS, et al. Predictors of trend in CD4 positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet 2004; 364: 51-62.
Deeks SG, Grant RM. Sustained CD4 responses after virological failure of protease inhibitor-containing therapy. Antivir Ther 1999; 4(Suppl 3): 7-11.
Deeks SG, Wrin T, Liegler T, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Eng J Med 2001; 344: 472-80.
Petersen ML, van der Laan MJ, Napravnik S, et al. Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification. AIDS 2008; 22: 2097-2106.
Anonymous. World Health Organization. Guidance on ethics and equitable access to HIV treatment and care. Geneva: WHO; 2004. http://www.who.int/ethics/en/ethics_equity_HIV_e.pdf (accessed on Oct 2009)
Morgan D, Mahe C, Mayanja B, et al. HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries? AIDS 2002; 16: 597-603.
Prendergast A, Tudor-Williams G, Jeena P, et al. International perspectives, progress, and future challenges of paediatric HIV infection. Lancet 2007; 370: 68-80.
Violari A, Cotton MF, Gibb DM, et al. Early antiretroviral therapy and mortality among HIV-infected infants. New Eng J Med 2008; 359: 2233-44.
Puthanakit T, Aurpibul L, Oberdorfer P, et al. Hospitalization and mortality among HIV-infected children after receiving highly active antiretroviral therapy. Clin Infect Dis 2007; 44: 599-604.
Jevtovic DJ, Salemovic D, Ranin J, Dulovic O, Ilic D, Brmbolic B. The prognosis of highly active antiretroviral therapy (HAART)-treated HIV infected patients in Serbia, related to the time of treatment initiation. J Clin Virol 2009; DOI: 10.1016/j.jcv.2009.11.017
Egger M, May M, Chena G, Philips AN, Ledergerber B, Dabis F, et al. ART Cohort Collaboration. Prognosis of HIV-1 infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360: 119-29.
Daniels N, Sabin J. Setting limits fairly: can we learn to share scarce medical resources? Cambridge: Oxford University Press; 2002.
Liss PE. Hard choices in public health: the allocation of scarce resources. Scand J Public Health 2003; 31: 156-7.
Eaton ML. Pharmacy ethics. In: Singer PA, Viens AM (eds). The Cambridge Textbook of Bioethics. Cambridge: Cambridge University Press; 2008.
Cressey TR, Leenasirimakul P, Jourdain G, et al. Low-doses of indinavir boosted with ritonavir in HIV-infected Thai patients: pharmacokinetics, efficacy and tolerability. J Antimicrob Chemother 2005; 55: 1041-4.
Mootsikapun P, Chetchotisakd P, Anunnatsiri S, Boonyaprawit P. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naïve HIV-1-infected patients with CD4+ T-cell counts<200 cells/mm3: 96-week outcomes. Antivir Ther 2005; 10: 911-16.
Duvivier L, Myrto M, Marcelin AG, et al. Efficacy and safety of ritonavir/indinavir 100/400 mg twice daily in combination with two nucleoside analogues in antiretroviral treatment-naïve HIV-infected individuals. Antivir Ther 2003; 8: 603-9.
| Files | ||
| Issue | Vol 3 (2010) | |
| Section | Articles | |
| Keywords | ||
| AIDS, Ethics, Rationing, Pharmacist. | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
